Your browser is no longer supported. Please, upgrade your browser.
Settings
RDHL [NASD]
RedHill Biopharma Ltd.
Index- P/E- EPS (ttm)-2.12 Insider Own0.22% Shs Outstand42.96M Perf Week3.54%
Market Cap339.72M Forward P/E- EPS next Y-0.07 Insider Trans0.00% Shs Float34.99M Perf Month19.80%
Income-81.90M PEG- EPS next Q-0.12 Inst Own25.30% Short Float5.65% Perf Quarter-7.34%
Sales83.90M P/S4.05 EPS this Y-46.80% Inst Trans34.07% Short Ratio6.78 Perf Half Y-13.06%
Book/sh1.23 P/B5.95 EPS next Y56.40% ROA-44.50% Target Price- Perf Year1.81%
Cash/sh1.64 P/C4.47 EPS next 5Y- ROE-251.50% 52W Range5.91 - 11.52 Perf YTD-9.41%
Dividend- P/FCF- EPS past 5Y-1.90% ROI-63.20% 52W High-36.46% Beta1.43
Dividend %- Quick Ratio1.60 Sales past 5Y635.00% Gross Margin45.80% 52W Low23.86% ATR0.31
Employees182 Current Ratio1.70 Sales Q/Q1249.70% Oper. Margin-77.30% RSI (14)57.77 Volatility4.45% 4.34%
OptionableYes Debt/Eq1.65 EPS Q/Q-9.40% Profit Margin-97.60% Rel Volume0.36 Prev Close7.28
ShortableYes LT Debt/Eq1.62 EarningsMay 27 BMO Payout- Avg Volume291.33K Price7.32
Recom1.70 SMA205.48% SMA506.49% SMA200-12.06% Volume103,586 Change0.55%
May-18-21Initiated H.C. Wainwright Buy $23
Sep-11-20Initiated BTIG Research Buy
Jul-12-19Upgrade WBB Securities Buy → Strong Buy
Mar-12-19Upgrade WBB Securities Speculative Buy → Buy
Jan-26-18Initiated Nomura Buy $18
Oct-06-17Initiated Seaport Global Securities Buy $19
Oct-04-17Reiterated H.C. Wainwright Buy $33 → $36
Feb-24-17Reiterated FBR & Co. Outperform $36 → $25
Jul-27-16Reiterated FBR Capital Outperform $33 → $36
Sep-29-15Initiated Nomura Buy
Jul-29-15Reiterated ROTH Capital Buy $30 → $31
Jun-17-15Reiterated H.C. Wainwright Buy $23 → $32
Jun-15-15Reiterated ROTH Capital Buy $27.50 → $30
Jun-09-21 07:00AM  
Jun-07-21 07:00AM  
May-27-21 07:15PM  
07:05AM  
07:00AM  
06:45AM  
May-26-21 11:06AM  
07:12AM  
07:00AM  
May-25-21 08:00AM  
May-24-21 07:00AM  
May-21-21 12:15PM  
May-20-21 07:00AM  
Apr-11-21 06:15AM  
Apr-09-21 07:00AM  
Mar-25-21 09:15AM  
Mar-22-21 07:00AM  
Mar-18-21 08:18AM  
Mar-11-21 07:00AM  
Mar-05-21 07:00AM  
Mar-04-21 12:10PM  
Mar-02-21 09:06AM  
08:23AM  
Mar-01-21 04:53PM  
Feb-23-21 08:07AM  
07:33AM  
07:13AM  
07:03AM  
Feb-18-21 01:00PM  
07:00AM  
Feb-17-21 07:00AM  
Feb-11-21 06:55AM  
Feb-09-21 07:00AM  
Jan-29-21 07:45AM  
07:26AM  
07:00AM  
Jan-28-21 09:03AM  
08:02AM  
07:27AM  
Jan-26-21 06:20AM  
Jan-14-21 02:13PM  
Jan-12-21 12:56PM  
08:51AM  
Jan-11-21 04:35PM  
07:00AM  
07:00AM  
Jan-08-21 02:11PM  
Jan-07-21 09:28AM  
Jan-06-21 07:00AM  
Jan-04-21 09:41AM  
Dec-31-20 09:38AM  
09:30AM  
Dec-28-20 11:28AM  
Dec-22-20 07:00AM  
Dec-15-20 11:42AM  
09:30AM  
Dec-14-20 08:00AM  
Dec-07-20 07:00AM  
Nov-29-20 09:45PM  
Nov-27-20 04:53PM  
11:32AM  
Nov-25-20 12:39PM  
10:36AM  
Nov-24-20 06:00PM  
Nov-23-20 09:00AM  
08:00AM  
Nov-20-20 08:00AM  
Nov-19-20 06:00PM  
07:21AM  
07:00AM  
Nov-18-20 06:00PM  
12:16PM  
Nov-17-20 10:11AM  
08:21AM  
07:00AM  
Nov-16-20 11:28AM  
10:13AM  
Nov-13-20 07:00AM  
Nov-12-20 07:00PM  
07:38AM  
07:00AM  
06:45AM  
Nov-11-20 10:14AM  
Nov-05-20 07:00AM  
Nov-04-20 10:30AM  
Oct-26-20 09:00AM  
Oct-15-20 10:26AM  
Oct-14-20 11:00AM  
Oct-13-20 11:24AM  
10:30AM  
Oct-08-20 10:30AM  
Oct-07-20 10:00AM  
Oct-06-20 07:00AM  
Sep-23-20 02:31PM  
12:46PM  
10:35AM  
10:25AM  
06:46AM  
Sep-22-20 10:00AM  
Sep-09-20 07:00AM  
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 1/2a study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and Phase 2a study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-106, an encapsulated formulation for bowel preparation, which has completed Phase 2a study. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.